UiPath - PATH Stock Forecast, Price & News

UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization. Its platform combines artificial intelligence with desktop recording, back-end mining of both human activity and system logs, and intuitive visualization tools, which enables users to discover, analyze, and identify processes to automate in a centralized portal; offers low-code development environments that allows users in an organization to create attended and unattended automations without any prior knowledge of coding; deploys robots in highly immersive attended experiences or in standalone, unattended modes behind the scenes, and can leverage native connectors built for commonly used line-of-business applications; offers centralized tools designed to manage, test, and deploy automations and ML models across the enterprise; allows customers to manage long running processes that orchestrate work between robots and humans; and enable users to track, measure, and forecast the performance of automation in their enterprise and help businesses ensure compliance with business standards. In addition, the company provides maintenance and support for its software, as well as professional services, such as training and implementation services to facilitate the adoption of its platform. It serves banking, healthcare, financial services, and government entities. UiPath Inc. was founded in 2005 and is headquartered in New York, New York.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PATH. BMO Capital Markets decreased their target price on UiPath from $29.00 to $21.00 in a research report on Thursday, June 2nd. Cowen decreased their price objective on UiPath from $43.00 to $27.00 in a research report on Friday, May 27th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $25.00 price objective on shares of UiPath in a research report on Thursday, July 7th. Wells Fargo & Company dropped their price objective on UiPath from $35.00 to $30.00 in a research note on Wednesday, May 18th. Finally, KeyCorp lowered their target price on UiPath from $34.00 to $23.00 and set an "overweight" rating on the stock in a report on Monday, April 25th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.06.

UiPath Stock Performance

Shares of NASDAQ:PATH opened at $20.70 on Monday. The stock has a fifty day moving average price of $19.64 and a two-hundred day moving average price of $23.28. The firm has a market cap of $11.28 billion, a P/E ratio of -26.88 and a beta of 0.09. UiPath has a 1 year low of $13.66 and a 1 year high of $65.60.

UiPath (NASDAQ:PATH - Get Rating) last announced its quarterly earnings data on Wednesday, June 1st. The healthcare company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.07). The company had revenue of $245.07 million for the quarter, compared to analyst estimates of $225.37 million. UiPath had a negative net margin of 42.95% and a negative return on equity of 18.47%. UiPath's revenue was up 31.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.81) EPS. On average, research analysts predict that UiPath will post -0.59 earnings per share for the current fiscal year.

Insider Activity

In other UiPath news, Director Kimberly Hammonds sold 2,521 shares of the stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $18.70, for a total transaction of $47,142.70. Following the transaction, the director now directly owns 100,662 shares of the company's stock, valued at $1,882,379.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 31.88% of the company's stock.